Powerwin Tech Group Limited (HKG:2405)

Intercept Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	0.54	7.19	5.49	5.78	5.89
Depreciation & Amortization	0.64	0.53	0.37	0.31	0.22
Other Amortization	0.08	0.01	0.01	0	-
Loss (Gain) From Sale of Assets	-	0.01	-	-	-0
Provision & Write-off of Bad Debts	0.74	1.45	0.3	0.16	0.77
Other Operating Activities	4.01	4.27	1.58	-0.34	1.61
Change in Accounts Receivable	-25.51	-90.41	23.18	-38.16	2.77
Change in Accounts Payable	0.06	30.71	2.26	3.83	-1.11
Change in Unearned Revenue	-0.1	-0.16	0.31	0.27	1.82
Operating Cash Flow	-19.55	-46.41	33.49	-28.14	11.98
Capital Expenditures	-0.01	-0.08	-0	-0.04	-0.02
Sale (Purchase) of Intangibles	-0.98	-1	-0.04	-0.01	-
Investment in Securities	-1.76	-1.19	-	-	-0.77
Investing Cash Flow	-2.75	-2.27	-0.04	-0.05	-0.79
Long-Term Debt Issued	610.21	601.48	462.76	500.85	385.95
Long-Term Debt Repaid	-569.35	-570.1	-479.9	-480.31	-381.29
Net Debt Issued (Repaid)	40.86	31.38	-17.14	20.55	4.65
Issuance of Common Stock	-	17.84	-	-	-
Common Dividends Paid	-	-1.3	-1.6	-	-
Other Financing Activities	-5.91	-5.19	-2.38	-1.37	-0.9
Financing Cash Flow	34.95	42.73	-21.12	19.18	3.75
Foreign Exchange Rate Adjustments	-0.07	0.04	-0.04	0	-0.05
Net Cash Flow	12.58	-5.9	12.29	-9.01	14.89
Free Cash Flow	-19.56	-46.49	33.49	-28.19	11.96
Free Cash Flow Margin	-145.33%	-216.18%	203.83%	-196.47%	102.34%
Free Cash Flow Per Share	-0.02	-0.06	0.06	-0.05	-
Cash Interest Paid	5.91	4.01	1.91	1.18	0.9
Cash Income Tax Paid	1.94	1.1	1.21	2.57	0.31
Levered Free Cash Flow	-27.03	-54.09	35.82	-25.02	9.78
Unlevered Free Cash Flow	-23.27	-51.5	37.02	-24.28	10.34
Change in Net Working Capital	26.73	58.6	-31.53	29.54	-5.26

Source: S&P Global Market Intelligence. Standard template. Financial Sources.